Overview
- Mexico’s 2025–2026 campaign runs from October 13 to April 3 with targets of 35.4 million influenza, 10.9 million COVID-19 and 4.2 million pneumococcal doses.
- The mix includes Moderna and Pfizer/BioNTech monovalent LP.8.1 COVID-19 vaccines, a domestically produced seasonal flu shot and a 20‑valent pneumococcal vaccine available at public facilities at no cost.
- Priority groups include children 6–59 months, adults 60+, pregnant women, people 5–59 with risk conditions and health workers, with no beneficiary status required at IMSS, ISSSTE and other public systems.
- Health authorities note contraindications, including avoiding COVID-19 vaccination after prior myocarditis and not recommending pneumococcal vaccination in pregnancy.
- Regional rollouts are active: Mexican states are using fixed sites and mobile brigades, Galicia’s school intranasal pilot has vaccinated about 250 children with roughly 50% participation so far, and Madrid has begun its flu/COVID campaigns with 1.68 million flu doses including 70,000 intranasal vials.